Funding for this research was provided by:
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham (No number)
the resources and use of facilities at the Birmingham VA Medical Center. (No number)
Received: 20 September 2019
Accepted: 4 February 2020
First Online: 19 February 2020
Ethics approval and consent to participate
: The study was approved by the Institutional Review Board (IRB) at the University of Alabama at Birmingham (UAB; IRB-120207004).
: No individual person’s data were presented in any form in this study, and therefore, no consent to publish is required.
: There are no financial conflicts related directly to this study. JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, the National Institutes of Health, and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS previously served as a member of the following committees: member, the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees; the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and the co-chair of the ACR Criteria and Response Criteria subcommittee. The other author declares that there are no competing interests.